Therapeutic monoclonal antibody concentration monitoring: free or total?
暂无分享,去创建一个
[1] J. S. Lee,et al. Widely varying TNF-α levels in patients with myasthenia gravis , 2009, Neurological Sciences.
[2] R H Levy,et al. Rationale for Monitoring Free Drug Levels , 1984, Clinical pharmacokinetics.
[3] J. Oh,et al. Detection of epidermal growth factor receptor in the serum of gastric carcinoma patients , 1997, Cancer.
[4] J. Arribas,et al. Protein ectodomain shedding. , 2002, Chemical reviews.
[5] G. Ciancio,et al. Anti-interleukin-2 receptor antibodies-basiliximab and daclizumab-for the prevention of acute rejection in renal transplantation , 2009 .
[6] Suzanne F. Jones,et al. A Phase 1 Escalating Single-Dose and Weekly Fixed-Dose Study of Cetuximab: Pharmacokinetic and Pharmacodynamic Rationale for Dosing , 2007, Clinical Cancer Research.
[7] L. Norton,et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] B. Meibohm,et al. Pharmacokinetic aspects of biotechnology products. , 2004, Journal of pharmaceutical sciences.
[9] R. Figlin,et al. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] P. Kuebler,et al. An Overview of the Pharmacokinetics and Pharmacodynamics of Efalizumab: A Monoclonal Antibody Approved for Use in Psoriasis , 2006, Journal of clinical pharmacology.
[11] M. Berger,et al. Pharmacokinetics of Gemtuzumab Ozogamicin, an Antibody‐Targeted Chemotherapy Agent for the Treatment of Patients with Acute Myeloid Leukemia in First Relapse , 2001, Journal of clinical pharmacology.
[12] M. Koller,et al. A safety and pharmacokinetic study of intravenous natalizumab in patients with MS , 1999, Neurology.
[13] P. Beer,et al. VITREOUS LEVELS OF UNBOUND BEVACIZUMAB AND UNBOUND VASCULAR ENDOTHELIAL GROWTH FACTOR IN TWO PATIENTS , 2006, Retina.
[14] G. Meno-Tetang,et al. On the prediction of the human response: a recycled mechanistic pharmacokinetic/pharmacodynamic approach. , 2005, Basic & clinical pharmacology & toxicology.
[15] Daniel H. S. Silverman,et al. Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin’s lymphoma , 2000, European Journal of Nuclear Medicine.
[16] L. Rassenti,et al. Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti‐CD52 antibodies , 2004, Cancer.
[17] Rene Bruno,et al. Clinical pharmacokinetics of bevacizumab in patients with solid tumors , 2008, Cancer Chemotherapy and Pharmacology.
[18] G. Paintaud,et al. Pharmacokinetics of rituximab and its clinical use: thought for the best use? , 2007, Critical reviews in oncology/hematology.
[19] Y. Tsukamoto,et al. A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab. , 2007, British journal of clinical pharmacology.
[20] B. Dijkmans,et al. Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis , 2004, Annals of the rheumatic diseases.
[21] F. Appelbaum,et al. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. , 1987, Blood.
[22] L. Goodman,et al. The Pharmacological Basis of Therapeutics , 1941 .
[23] G. Sledge,et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] J. Fox,et al. Tissue distribution and complex formation with IgE of an anti-IgE antibody after intravenous administration in cynomolgus monkeys. , 1996, The Journal of pharmacology and experimental therapeutics.
[25] J. Pulido,et al. Pharmacokinetics of intravitreal bevacizumab (Avastin). , 2007, Ophthalmology.
[26] Wei-Ching Liang,et al. Technology comparisons for anti-therapeutic antibody and neutralizing antibody assays in the context of an anti-TNF pharmacokinetic study. , 2009, Journal of immunological methods.
[27] R. Slavin,et al. Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations. , 2009, The Journal of allergy and clinical immunology.
[28] A. Balcerska,et al. Serum soluble interleukin 2 receptor α in human cancer of adults and children: a review , 2008 .
[29] E. Kubista,et al. Serum EGFR levels and efficacy of trastuzumab-based therapy in patients with metastatic breast cancer. , 2006, European journal of cancer.
[30] L. Steinman,et al. Administration of Neutralizing Antibodies to Interleukin-6 (IL-6) Reduces Experimental Autoimmune Encephalomyelitis and Is Associated with Elevated Levels of IL-6 Bioactivity in Central Nervous System and Circulation , 1995, Molecular medicine.
[31] R. Eckert,et al. In Vitro Internalization, Intracellular Transport, and Clearance of an Anti-CD11a Antibody (Raptiva) by Human T-Cells , 2004, Journal of Pharmacology and Experimental Therapeutics.
[32] I. Pastan,et al. High Shed Antigen Levels within Tumors: An Additional Barrier to Immunoconjugate Therapy , 2008, Clinical Cancer Research.
[33] G. Hale,et al. Pharmacokinetics of CAMPATH-1H: assay development and validation. , 2002, Journal of immunological methods.
[34] T. Illidge,et al. A new anti-idiotype antibody capable of binding rituximab on the surface of lymphoma cells. , 2004, Blood.
[35] L. Steinman. Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab , 2005, Nature Reviews Drug Discovery.
[36] I Royston,et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. , 1997, Blood.
[37] A. Nagler,et al. Soluble interleukin-2 receptor levels in cytomegalovirus disease and graft versus host disease after T-lymphocyte depleted bone marrow transplantation for hematological neoplasias. , 1994, Leukemia & lymphoma.
[38] K. Do,et al. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. , 2003, Blood.
[39] F. Breedveld,et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. , 1999, Journal of immunology.
[40] D. Marmé,et al. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease , 1999, Cancer.
[41] D. S. Riggs,et al. Thyroid function in nephrosis. , 1952, The Journal of clinical investigation.
[42] R. Tacey,et al. Development and validation of ELISA for herceptin detection in human serum. , 2004, Journal of immunological methods.
[43] Helen J. Lachmann,et al. In vivo regulation of interleukin 1β in patients with cryopyrin-associated periodic syndromes , 2009, The Journal of experimental medicine.
[44] P. Hawkins,et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. , 2009, The New England journal of medicine.
[45] W Wang,et al. Monoclonal Antibody Pharmacokinetics and Pharmacodynamics , 2008, Clinical pharmacology and therapeutics.
[46] C. Maury,et al. Radioimmunoassay of tumor necrosis factor in serum. , 1987, Clinical chemistry.
[47] M. Blumenthal,et al. Robustness into advanced age of atopy-specific mechanisms in atopy-prone families. , 2003, The journals of gerontology. Series A, Biological sciences and medical sciences.
[48] J. Grandis,et al. Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation. , 2004, Cancer treatment reviews.
[49] D. Norman. Mechanisms of Action and Overview of OKT3 , 1995, Therapeutic drug monitoring.
[50] M. Maurel,et al. Evaluation of a peptide ELISA for the detection of rituximab in serum. , 2007, Journal of immunological methods.
[51] J. Schölmerich,et al. Inadequately low serum levels of steroid hormones in relation to interleukin-6 and tumor necrosis factor in untreated patients with early rheumatoid arthritis and reactive arthritis. , 2002, Arthritis and rheumatism.
[52] L. Matis,et al. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. , 1996, Molecular immunology.
[53] N. Hogg,et al. Shedding of lymphocyte function-associated antigen-1 (LFA-1) in a human inflammatory response. , 2006, Blood.
[54] S. A. Bush,et al. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. , 2000, Blood.
[55] I. T. Ten Berge,et al. Pharmacokinetics of murine anti-human CD3 antibodies in man are determined by the disappearance of target antigen. , 2002, The Journal of pharmacology and experimental therapeutics.
[56] Stanley B. Cohen,et al. Pharmacokinetics and Safety of Golimumab, a Fully Human Anti‐TNF‐α Monoclonal Antibody, in Subjects With Rheumatoid Arthritis , 2007, Journal of clinical pharmacology.
[57] D. Mould,et al. Determination of humanized anti-Tac in human serum by a sandwich enzyme linked immunosorbent assay. , 1995, Journal of immunological methods.
[58] J. Pulido,et al. SIX-MONTH STABILITY OF BEVACIZUMAB (AVASTIN) BINDING TO VASCULAR ENDOTHELIAL GROWTH FACTOR AFTER WITHDRAWAL INTO A SYRINGE AND REFRIGERATION OR FREEZING , 2006, Retina.
[59] L. Joosten,et al. Effects of treatment with a fully human anti-tumour necrosis factor α monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFα in patients with rheumatoid arthritis , 2001, Annals of the rheumatic diseases.
[60] Janice M Reichert,et al. Monoclonal antibodies as innovative therapeutics. , 2008, Current pharmaceutical biotechnology.
[61] J. Baselga,et al. Utility of serum HER2 extracellular domain assessment in clinical decision making: pooled analysis of four trials of trastuzumab in metastatic breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[62] P. Tak,et al. Clinical response, pharmacokinetics, development of human anti-chimaeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis , 2009, Annals of the rheumatic diseases.
[63] S. Richards,et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. , 2004, The New England journal of medicine.
[64] N. Damle. Tumour-targeted chemotherapy with immunoconjugates of calicheamicin , 2004, Expert opinion on biological therapy.
[65] D Tripathy,et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[66] R. Ariagno,et al. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. , 1998, The Pediatric infectious disease journal.
[67] Eleftherios P. Diamandis,et al. 3 – THEORY OF IMMUNOASSAYS , 1996 .
[68] G. Paintaud,et al. An Enzyme-Linked Immunosorbent Assay for Therapeutic Drug Monitoring of Cetuximab , 2009, Therapeutic drug monitoring.
[69] M. Tabrizi,et al. Elimination mechanisms of therapeutic monoclonal antibodies. , 2006, Drug discovery today.
[70] R. Hamilton,et al. Immunological methods for quantifying free and total serum IgE levels in allergy patients receiving omalizumab (Xolair) therapy. , 2005, Journal of immunological methods.
[71] Y. Sasaki,et al. Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer , 1999, British Journal of Cancer.
[72] H. Booker,et al. Serum Concentrations of Free Diphenylhydantoin and their Relationship To Clinical Intoxication , 1973, Epilepsia.
[73] N. Rawal,et al. C5 Convertase of the Alternative Pathway of Complement , 1998, The Journal of Biological Chemistry.
[74] A. Kennedy,et al. Three new assays for rituximab based on its immunological activity or antigenic properties: analyses of sera and plasmas of RTX-treated patients with chronic lymphocytic leukemia and other B cell lymphomas. , 2004, Journal of immunological methods.
[75] S. Tannenbaum,et al. Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma. , 2009, British journal of clinical pharmacology.
[76] D Tripathy,et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[77] H. Paulus,et al. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. , 2003, Clinical therapeutics.
[78] R. Hansen,et al. Antibody pharmacokinetics and pharmacodynamics. , 2004, Journal of pharmaceutical sciences.
[79] R. Dockhorn,et al. Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. , 1997, The Journal of allergy and clinical immunology.
[80] E. Raymond,et al. Pharmacokinetic profile of cetuximab (Erbitux) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma. , 2005, European journal of cancer.
[81] J. Armitage,et al. Circulating CD20 and CD52 in patients with non‐Hodgkin's lymphoma or Hodgkin's disease , 2003, British journal of haematology.
[82] B. Meibohm,et al. Population Pharmacokinetics of Cetuximab in Patients With Squamous Cell Carcinoma of the Head and Neck , 2008, Journal of clinical pharmacology.
[83] N. Casadevall,et al. The immunophenotype of 177 adults with acute myeloid leukemia: proposal of a prognostic score. , 2000, Blood.
[84] J. E. Rall,et al. The interaction of thyroid hormones and protein in biological fluids. , 1957, Recent progress in hormone research.
[85] H. Kantarjian,et al. Alemtuzumab: validation of a sensitive and simple enzyme-linked immunosorbent assay. , 2004, Leukemia research.